CompletedPhase 3NCT00220766

Rapid Infusion of Immune Globulin Intravenous (Human) In Primary Immunodeficiency Patients

Studying Wiskott-Aldrich syndrome

Last synced from ClinicalTrials.gov May 3, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Grifols Therapeutics LLC
Principal Investigator: Erwin Gelfand, MD, M.D., Ph.D
National Jewish Medical and Research Center, Denver, CO
Intervention: Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified(drug)
Enrollment: 100 enrolled
Eligibility: 18-75 years · All sexes
Timeline: 2002 – 2004

Study locations (13)

Departments of Medicine and Microbiology, Birmingham, Alabama, United States
National Jewish Medical and Researach Center, Denver, Colorado, United States
International Center for Interdisciplinary Studies of Immunology, Washington D.C., District of Columbia, United States
Allergy Associates of the Palm Beaches, North Palm Beach, Florida, United States
University of South Florida College of Medicine, St. Petersburg, Florida, United States
The Clinical Trials Center, Children's Hospital, New Orleans, Louisiana, United States
Allergy, Asthma, and Immunology, Omaha, Nebraska, United States
University Hospitals of Cleveland, Cleveland, Ohio, United States
Optimed Research, LLC, Columbus, Ohio, United States
3031 Hospital Drive Northwest, Calgary, Alberta, Canada
St. Paul's Hospital, Vancouver, British Columbia, Canada
Saint Michael's Hospital, Toronto, Ontario, Canada
The Hospital for Sick Children, Toronto, Ontario, Canada

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00220766 on ClinicalTrials.gov

Other trials for Wiskott-Aldrich syndrome

Additional recruiting or active studies for the same condition.

See all trials for Wiskott-Aldrich syndrome →

← Back to all trials